Peptide & GLP-1 News
Research updates, regulatory changes, and industry developments — reported with context, not hype.
Featured
RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the FDA Category 2 restricted list will return to Category 1 — restoring legal compounding access.
Ozempic Side Effects: What 5 Years of Real-World Data Actually Shows
With over 5 years of real-world prescribing data, the side effect profile of semaglutide is now well-characterized. We break down what the evidence shows — from common GI effects to the concerns making headlines.
Oral Wegovy Pill Gets FDA Approval: What You Need to Know
The FDA approved oral semaglutide (Wegovy pill) for chronic weight management in December 2025 — eliminating the need for weekly injections. Here is what the clinical data shows.
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
The SURMOUNT-5 trial settled the debate: tirzepatide produces 47% more weight loss than semaglutide. But the full picture is more nuanced than the headline.
All Articles
Retatrutide Phase 3: Triple Agonist Delivers 71 lbs Average Weight Loss
Eli Lilly's triple-agonist retatrutide delivered an average 71.2 lbs of weight loss in the TRIUMPH-4 Phase 3 trial — plus significant osteoarthritis pain relief. Seven more Phase 3 trials report in 2026.
Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
Analysis shows generic semaglutide could be produced for $3/month. With patents expiring in 8 countries in 2026, the cost landscape for Ozempic and Wegovy is about to change dramatically.
FDA Category 2 Peptide Ban: The Complete Guide
Everything you need to know about the FDA's Category 2 classification of peptides — which compounds are affected, what it means for access, and the 2026 reclassification reversal.
How to Prevent Muscle Loss on Ozempic and Other GLP-1 Drugs
Up to 40% of weight lost on GLP-1 drugs can be lean mass. The medical consensus is clear: resistance training during GLP-1 therapy is essential, not optional.
"Ozempic Face" Explained: What Causes It and What Helps
"Ozempic face" — facial sagging and volume loss during rapid weight loss — is not caused by semaglutide specifically. It happens with any significant weight loss. Here is what the evidence says.
Peptide Compounding in 2026: What Patients Need to Know
With the 2026 FDA reclassification restoring access to many peptides, compounding is back in focus. Here is what you need to know about quality, safety, and choosing a pharmacy.
GLP-1 Drugs and Cancer Risk: What the Research Actually Shows
The thyroid cancer boxed warning. The cancer-protective speculation. A 50-trial meta-analysis. Here is what the evidence actually says about GLP-1 medications and cancer risk.
2026 Weight Loss Drug Pipeline: What Comes After Ozempic
Retatrutide, orforglipron, CagriSema, and more — the next wave of obesity drugs promises even greater weight loss, oral delivery, and new mechanisms. Here is the full pipeline.
Tirzepatide 3-Year Data: Weight Loss Sustained at 22.9%
The SURMOUNT-1 three-year extension confirms what patients needed to know: tirzepatide weight loss holds steady through year 3 with continued treatment.
Eli Lilly Warns of Counterfeit Tirzepatide: How to Stay Safe
Eli Lilly is pursuing legal action against sellers of counterfeit tirzepatide. Testing found products containing bacteria, impurities, and in one case only sugar alcohol.
How GLP-1 Drugs Are Cutting America's Grocery Bills
A Cornell study found households on GLP-1 drugs cut grocery spending by over 5% within 6 months, with even bigger drops at fast-food restaurants. The food industry is taking notice.
BPC-157 Human Clinical Data: Where We Stand in 2026
With the FDA reclassification restoring compounding access, BPC-157 is back in focus. Here is an honest assessment of where the human evidence stands.
Novo Nordisk Slashes GLP-1 Prices 70%: What It Means for Patients
Novo Nordisk announced up to 70% price cuts on its GLP-1 medications in early 2026. We analyze what this actually means for patient out-of-pocket costs.
FDA Approves Monthly Tirzepatide KwikPen for Weight Management
The new Zepbound KwikPen packs 4 weekly doses into one device — a full month of treatment. Available at $299/month for the starting dose via LillyDirect.
GLP-1 Drugs and Reduced Alcohol Consumption: An Unexpected Effect
Patients on Ozempic and Wegovy increasingly report reduced desire to drink alcohol. The neuroscience behind this effect is becoming clearer — and clinical trials are underway.
Peptides Go Mainstream: NPR, MIT Tech Review, and PolitiFact Cover the Trend
In a single week in February 2026, NPR, MIT Technology Review, and PolitiFact all published major pieces on the peptide trend. We analyze their coverage.